26 June 2020 : Clinical Research
Hepatitis B Surface Antigen (HBsAg) Kinetics in Chronic Hepatitis B Patients during Peginterferon Treatment
Kaifa Wang1AEG, Guangyu Huang2BCF*, Yagang Chen2DF, Yuming Wang34BFDOI: 10.12659/MSM.921487
Med Sci Monit 2020; 26:e921487
Table 2 The distributions of age, sex, baseline HBsAg for uncured patients.
| Baseline HBsAg (IU/mL) | Cases | Age (years) | Male | Female |
|---|---|---|---|---|
| (0, 10) | 8 (6) | 38.33±8.24 (37.13±7.54) | 6 (5) | 2 (1) |
| (10, 75) | 21 (19) | 35.95±5.92 (36.57±5.96) | 20 (19) | 1 (0) |
| (75, 600) | 24 (18) | 38.44±7.02 (39.13±8.19) | 15 (11) | 9 (7) |
| (600, 1000) | 22 (18) | 39.00±8.60 (37.91±8.57) | 17 (15) | 5 (3) |
| (1000, 5000) | 30 (25) | 37.08±5.28 (37.40±5.51) | 25 (20) | 5 (5) |
| (5000, 10000) | 11 (10) | 33.40±6.02 (33.27±5.75) | 10 (9) | 1 (1) |
| (10000, 20000) | 8 (7) | 35.00±6.39 (33.50±7.18) | 5 (4) | 3 (3) |
| (20000, ∞) | 14 (13) | 34.85±5.27 (34.86±5.08) | 11 (10) | 3 (3) |
| Numbers outside the bracket are data for 138 uncured patients. The numbers within the bracket are data for the screened 116 patients, i.e., treatment duration longer than or equal to 56 days. | ||||